MCRB - セレス・セラピュ―ティックス (Seres Therapeutics Inc.)

MCRBのニュース

   Seres Therapeutics to Present at Upcoming Investor Conferences  2020/09/14 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced that management will present at two upcoming investor conferences: H.C. Wainwright 22nd Annual Global Investment Conference: Seres will present a corporate overview on Wednesday, September 16 at 11:00 a.m. ET. Oppenheimer Fall Healthcare Summit: Seres will present a corporate overview on Wednesday, September 23 at 11:40 a.m. ET. A live audio webcast of each presentation will be available under the “Investo
   Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results  2020/09/11 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it has obtained correspondence from the Office of Vaccines Research and Review of the U.S. Food and Drug Administration (FDA) regarding the Company’s plans to submit a Biologics License Application (BLA) to support product approval of SER-109 for recurrent C. difficile infection (CDI). After obtaining highly statistically significant topline Phase 3 ECOSPOR III SER-109 study results in recurrent CDI,
   Human Microbiome Therapeutics Market Analysis Highlights the Impact of COVID-19 (2020-2024) | Growing Prevalence of Chronic Diseases to Boost the Market Growth | Technavio  2020/08/31 21:15:00 Benzinga
Technavio has been monitoring the human microbiome therapeutics market and it is poised to grow by USD 276.93 mn during 2020-2024, progressing at a CAGR of almost 15% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200831005526/en/ Technavio has announced its latest market research report titled Global Human Microbiome Therapeutics Market 2020-2024 (Graphic: Business Wire) Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavio's in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis.
   The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September  2020/08/11 12:20:27 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Allovir Inc (NASDAQ: ALVR ) BioLife Solutions Inc (NASDAQ: BLFS ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (reacted to second-quarter results) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Fulgent Genetics Inc (NASDAQ: FLGT ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Inari Medical Inc (NASDAQ: NARI ) Kura Oncology Inc (NASDAQ: KURA ) Omeros Corporation (NASDAQ: OMER ) ( announced positive results for the study of its lead asset in COVID-19) Pacira Biosciences Inc (NASDAQ: PCRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Seres Therapeutics Inc (NASDAQ: MCRB ) ( reacted to positive late-stage clinical readout) Silk Road Medical Inc (NASDAQ: SILK ) Sorrento Therapeutics Inc (NASDAQ: SRNE ) Trevena Inc (NASDAQ: TRVN ) (announced FDA nod for pain drug) Unity Biotechnology Inc (NASDAQ: UBX ) Vaxcyte Inc (NASDAQ: PCVX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 10) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI ) (went public Friday) Freeline Therapeutics Holdings plc ADS (NASDAQ: FRLN ) (went public Friday) Lantern Pharma Inc. (NASDAQ: LTRN ) Nkarta Inc (NASDAQ: NKTX ) Recro Pharma Inc (NASDAQ: REPH ) (reacted to second-quarter results) Stocks In Focus Equillium Announces Positive Interim Data For Lead Drug, Requests Pre-IND Meeting For COVID-19 Study Equillium Inc (NASDAQ: EQ ) announced positive interim data from the first two cohorts of the Phase 1b open label, dose escalation portion of the EQUATE study of itolizumab in acute graft-versus-host disease.
   A biotech stock just rocketed 608% after announcing positive phase 3 trial data (MCRB)  2020/08/10 19:50:26 Business Insider
Seres Therapeutics soared as much as 608% on Monday after the company announced positive phase 3 trial data for its drug SER-109. SER-109 was developed for the potential treatment of C. difficile, which is a bacterial infection of the colon that leads to inflammation and can be deadly. Seres said that SER-109 was well tolerated by its trial participants and that it led to a 30.2% decline in the rate of C. difficile recurrence relative to the placebo. Seres' market valuation soared from $354 million on Friday to more than $1.5 billion as of Monday afternoon, according to data from YCharts.com Visit Business Insider's homepage for more stories . A tiny biotech stock rewarded investors on Monday after it announced positive phase 3 trial data. The company, Seres Therapeutics, released positive phase 3 trial data for its SER-109 drug, which was being tested for potential treatment of C. difficile. C. difficile is a bacterial infection of the colon that leads to inflammation and can be deadly.
   The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September  2020/08/11 12:20:27 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Allovir Inc (NASDAQ: ALVR ) BioLife Solutions Inc (NASDAQ: BLFS ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (reacted to second-quarter results) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Fulgent Genetics Inc (NASDAQ: FLGT ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Inari Medical Inc (NASDAQ: NARI ) Kura Oncology Inc (NASDAQ: KURA ) Omeros Corporation (NASDAQ: OMER ) ( announced positive results for the study of its lead asset in COVID-19) Pacira Biosciences Inc (NASDAQ: PCRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Seres Therapeutics Inc (NASDAQ: MCRB ) ( reacted to positive late-stage clinical readout) Silk Road Medical Inc (NASDAQ: SILK ) Sorrento Therapeutics Inc (NASDAQ: SRNE ) Trevena Inc (NASDAQ: TRVN ) (announced FDA nod for pain drug) Unity Biotechnology Inc (NASDAQ: UBX ) Vaxcyte Inc (NASDAQ: PCVX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 10) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI ) (went public Friday) Freeline Therapeutics Holdings plc ADS (NASDAQ: FRLN ) (went public Friday) Lantern Pharma Inc. (NASDAQ: LTRN ) Nkarta Inc (NASDAQ: NKTX ) Recro Pharma Inc (NASDAQ: REPH ) (reacted to second-quarter results) Stocks In Focus Equillium Announces Positive Interim Data For Lead Drug, Requests Pre-IND Meeting For COVID-19 Study Equillium Inc (NASDAQ: EQ ) announced positive interim data from the first two cohorts of the Phase 1b open label, dose escalation portion of the EQUATE study of itolizumab in acute graft-versus-host disease.
   A biotech stock just rocketed 608% after announcing positive phase 3 trial data (MCRB)  2020/08/10 19:50:26 Business Insider
Seres Therapeutics soared as much as 608% on Monday after the company announced positive phase 3 trial data for its drug SER-109. SER-109 was developed for the potential treatment of C. difficile, which is a bacterial infection of the colon that leads to inflammation and can be deadly. Seres said that SER-109 was well tolerated by its trial participants and that it led to a 30.2% decline in the rate of C. difficile recurrence relative to the placebo. Seres' market valuation soared from $354 million on Friday to more than $1.5 billion as of Monday afternoon, according to data from YCharts.com Visit Business Insider's homepage for more stories . A tiny biotech stock rewarded investors on Monday after it announced positive phase 3 trial data. The company, Seres Therapeutics, released positive phase 3 trial data for its SER-109 drug, which was being tested for potential treatment of C. difficile. C. difficile is a bacterial infection of the colon that leads to inflammation and can be deadly.
   Seres Therapeutics Skyrockets On Positive Pivotal Study Results For Microbiome Therapeutic  2020/08/10 15:25:03 Benzinga
Shares of the small-cap biopharma Seres Therapeutics Inc (NASDAQ: MCRB ) were ripping higher Monday. What Happened: Cambridge, Massachusetts-based Seres announced positive topline results from a pivotal Phase 3 study, dubbed ECOSPOR III, that is evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection. The study met the primary endpoint of showing a statistically significant absolute decrease of 30.2% in the proportion of patients who experienced a recurrence in CDI within eight weeks of administration of SER-109 versus placebo, the company said. Additionally, 11.1% of patients in the treatment arm experienced a CDI recurrence versus 41.3% in the … Full story available on Benzinga.com
   Seres Therapeutics : SER 109 ECOSPOR III top line study results | MarketScreener  2020/08/10 14:09:05 MarketScreener
Seres Therapeutics Overview SER-109 ECOSPOR III top-line study results August 10, 2020 Forward… | August 10, 2020
   Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection  2020/08/10 10:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $MCRB--SER-109 met Phase 3 primary endpoint, showing highly statistically significant 30.2% absolute reduction in the rate of C. diff infection recurrence.
   The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September  2020/08/11 12:20:27 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Allovir Inc (NASDAQ: ALVR ) BioLife Solutions Inc (NASDAQ: BLFS ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (reacted to second-quarter results) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Fulgent Genetics Inc (NASDAQ: FLGT ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Inari Medical Inc (NASDAQ: NARI ) Kura Oncology Inc (NASDAQ: KURA ) Omeros Corporation (NASDAQ: OMER ) ( announced positive results for the study of its lead asset in COVID-19) Pacira Biosciences Inc (NASDAQ: PCRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Seres Therapeutics Inc (NASDAQ: MCRB ) ( reacted to positive late-stage clinical readout) Silk Road Medical Inc (NASDAQ: SILK ) Sorrento Therapeutics Inc (NASDAQ: SRNE ) Trevena Inc (NASDAQ: TRVN ) (announced FDA nod for pain drug) Unity Biotechnology Inc (NASDAQ: UBX ) Vaxcyte Inc (NASDAQ: PCVX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 10) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI ) (went public Friday) Freeline Therapeutics Holdings plc ADS (NASDAQ: FRLN ) (went public Friday) Lantern Pharma Inc. (NASDAQ: LTRN ) Nkarta Inc (NASDAQ: NKTX ) Recro Pharma Inc (NASDAQ: REPH ) (reacted to second-quarter results) Stocks In Focus Equillium Announces Positive Interim Data For Lead Drug, Requests Pre-IND Meeting For COVID-19 Study Equillium Inc (NASDAQ: EQ ) announced positive interim data from the first two cohorts of the Phase 1b open label, dose escalation portion of the EQUATE study of itolizumab in acute graft-versus-host disease.
   A biotech stock just rocketed 608% after announcing positive phase 3 trial data (MCRB)  2020/08/10 19:50:26 Business Insider
Seres Therapeutics soared as much as 608% on Monday after the company announced positive phase 3 trial data for its drug SER-109. SER-109 was developed for the potential treatment of C. difficile, which is a bacterial infection of the colon that leads to inflammation and can be deadly. Seres said that SER-109 was well tolerated by its trial participants and that it led to a 30.2% decline in the rate of C. difficile recurrence relative to the placebo. Seres' market valuation soared from $354 million on Friday to more than $1.5 billion as of Monday afternoon, according to data from YCharts.com Visit Business Insider's homepage for more stories . A tiny biotech stock rewarded investors on Monday after it announced positive phase 3 trial data. The company, Seres Therapeutics, released positive phase 3 trial data for its SER-109 drug, which was being tested for potential treatment of C. difficile. C. difficile is a bacterial infection of the colon that leads to inflammation and can be deadly.
   Seres Therapeutics Skyrockets On Positive Pivotal Study Results For Microbiome Therapeutic  2020/08/10 15:25:03 Benzinga
Shares of the small-cap biopharma Seres Therapeutics Inc (NASDAQ: MCRB ) were ripping higher Monday. What Happened: Cambridge, Massachusetts-based Seres announced positive topline results from a pivotal Phase 3 study, dubbed ECOSPOR III, that is evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection. The study met the primary endpoint of showing a statistically significant absolute decrease of 30.2% in the proportion of patients who experienced a recurrence in CDI within eight weeks of administration of SER-109 versus placebo, the company said. Additionally, 11.1% of patients in the treatment arm experienced a CDI recurrence versus 41.3% in the … Full story available on Benzinga.com
   Seres Therapeutics : SER 109 ECOSPOR III top line study results | MarketScreener  2020/08/10 14:09:05 MarketScreener
Seres Therapeutics Overview SER-109 ECOSPOR III top-line study results August 10, 2020 Forward… | August 10, 2020
   Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection  2020/08/10 10:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $MCRB--SER-109 met Phase 3 primary endpoint, showing highly statistically significant 30.2% absolute reduction in the rate of C. diff infection recurrence.

calendar